Novo Nordisk's diabetes drug now approved to prevent heart attacks, strokes

The Food and Drug Administration on Friday approved an expanded use for Novo Nordisk's diabetes drug Victoza.

The agency first approved Victoza to treat patients with type 2 diabetes in 2010. The drug may now be used to reduce the risk of cardiovascular events — like heart attacks and strokes — in this patient population.

The expanded approval stems from a clinical trial, which showed Victoza reduced the risk of cardiovascular events by 13 percent compared to a placebo.

More articles on supply chain:

7 drugmakers in the headlines
Gilead to acquire Kite Pharma for nearly $12B: 4 things to know
Blood supplier expects shortages in Texas amid Hurricane Harvey

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars